Dublin, 5th April 2023: An innovative new project aiming to develop a personalised prediction tool to assist in managing the recurrence of autoimmune diseases in a patient has officially been launched with the ADAPT Centre this week. PARADISE, PersonAlisation of RelApse risk in autoimmune DISEase, kicked off officially on the 3rd and 4th of April 2023 featuring presentations from ADAPT researchers Matthieu Coq, Yagmur Dogay, Angel George, and Jamsheela Nazeer. The project is coordinated by ADAPT Principal Investigator at Trinity College Dublin, Prof. Mark Little, with partners across several institutions in Europe.
According to the PARADISE consortium, autoimmune disease affects 10% of all adults and, in particular, women are the most affected by these diseases. Medications to manage these conditions also have a very high cost globally and work to suppress the immune system, which often leads to patients becoming more susceptible to increased infection and cancer risk. A key target for research by the PARADISE consortium is the prediction of relapse, or those patients in whom relapse is extremely unlikely, for patients with Vasculitis so that medication doses can be tailored or in some cases, stopped entirely.
As artificial intelligence (AI) applications are coming under intense EU scrutiny, the consortium will also co-develop an “AI transparency notice” so as to explicitly explain the PARADISE tools clinical outputs.
Project partners include:
Photo: Mark Little presenting at the PARADISE launch.
Twitter feed is not available at the moment.